clavubactin vet. (clavoral) tafla 250/62,5 mg
le vet b.v.* - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 250/62,5 mg
clavubactin vet. (clavoral) tafla 50/12,5 mg
le vet b.v.* - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 50/12,5 mg
spectrabactin vet tafla 200 mg/50 mg
dechra regulatory b.v. - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 200 mg/50 mg
spectrabactin vet tafla 40 mg/10 mg
dechra regulatory b.v. - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 40 mg/10 mg
keflex mixtúrukyrni, dreifa 50 mg/ml
stada nordic aps. - cefalexinum mónóhýdrat - mixtúrukyrni, dreifa - 50 mg/ml
keflex tafla 500 mg
stada nordic aps. - cefalexinum mónóhýdrat - tafla - 500 mg
zinforo
pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - sýklalyf fyrir almenn nota, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.
aprokam (cefcam) stungulyfsstofn, lausn 50 mg
laboratoires thea* - cefuroximum natríum - stungulyfsstofn, lausn - 50 mg
amoxicillin sandoz mixtúruduft, dreifa 100 mg/ml
sandoz a/s* - amoxicillinum tríhýdrat - mixtúruduft, dreifa - 100 mg/ml
cefabactin vet tafla 50 mg
le vet beheer b.v. - cefalexinum mónóhýdrat - tafla - 50 mg